The company has developed a non-steroidal, non-immunosuppresive small molecule drug that has a first in class mechanism of action - acting on a new pathway rather than non specifically inhibiting the immune system. A "first-in-class" mechanism in drugs is special because it represents a completely novel approach to treating a disease, often targeting pathways or biological processes that have never been addressed by existing therapies. Ahammune’s innovative mechanism of action opens up the possibility of treating vitiligo effectively, economically and without side effects.